金斯瑞(01548.HK)附屬傳奇生物LB1901臨牀試驗已暫停
金斯瑞生物科技(01548.HK)公佈,非全資附屬傳奇生物收到美國食品藥品監督管理局(FDA)通知,其LB1901的1期臨牀試驗已暫停進行。
LB1901是傳奇生物的一項針對惡性CD4+T細胞的試驗性自體嵌合抗原受體T細胞療法。至今,已經有一名患者在該項臨牀試驗中接受了注射。在收到FDA臨牀暫停通知之前,出於患者外周血CD4+T細胞計數低的原因,傳奇生物依照試驗方案已經暫停了該臨牀試驗並通知了FDA。該名患者未發生藥物相關嚴重不良事件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.